386 related articles for article (PubMed ID: 29121337)
21. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
22. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
Wiśnik E; Ryksa M; Koter-Michalak M
Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104
[TBL] [Abstract][Full Text] [Related]
23. PARPs' impact on base excision DNA repair.
Lavrik OI
DNA Repair (Amst); 2020 Sep; 93():102911. PubMed ID: 33087277
[TBL] [Abstract][Full Text] [Related]
24. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
25. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
26. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
[TBL] [Abstract][Full Text] [Related]
27. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.
Zentout S; Imburchia V; Chapuis C; Duma L; Schützenhofer K; Prokhorova E; Ahel I; Smith R; Huet S
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322689121. PubMed ID: 38865276
[TBL] [Abstract][Full Text] [Related]
28. Dynamic light scattering study of base excision DNA repair proteins and their complexes.
Vasil'eva IA; Anarbaev RO; Moor NA; Lavrik OI
Biochim Biophys Acta Proteins Proteom; 2019 Mar; 1867(3):297-305. PubMed ID: 30321662
[TBL] [Abstract][Full Text] [Related]
29. The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.
Kamaletdinova T; Fanaei-Kahrani Z; Wang ZQ
Cells; 2019 Dec; 8(12):. PubMed ID: 31842403
[TBL] [Abstract][Full Text] [Related]
30. Phosphatase 1 Nuclear Targeting Subunit Mediates Recruitment and Function of Poly (ADP-Ribose) Polymerase 1 in DNA Repair.
Wang F; Zhu S; Fisher LA; Wang L; Eurek NJ; Wahl JK; Lan L; Peng A
Cancer Res; 2019 May; 79(10):2526-2535. PubMed ID: 30733193
[TBL] [Abstract][Full Text] [Related]
31. Dynamic action of DNA repair proteins as revealed by single molecule techniques: Seeing is believing.
Kong M; Beckwitt EC; Van Houten B
DNA Repair (Amst); 2020 Sep; 93():102909. PubMed ID: 33087275
[TBL] [Abstract][Full Text] [Related]
32. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Ferrarotto R; Cardnell R; Su S; Diao L; Eterovic AK; Prieto V; Morrisson WH; Wang J; Kies MS; Glisson BS; Byers LA; Bell D
Head Neck; 2018 Aug; 40(8):1676-1684. PubMed ID: 29570891
[TBL] [Abstract][Full Text] [Related]
33. Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs.
Rudolph J; Roberts G; Luger K
Nat Commun; 2021 Feb; 12(1):736. PubMed ID: 33531508
[TBL] [Abstract][Full Text] [Related]
34. Identification and quantification of DNA repair protein poly(ADP ribose) polymerase 1 (PARP1) in human tissues and cultured cells by liquid chromatography/isotope-dilution tandem mass spectrometry.
Coskun E; Tuna G; Jaruga P; Tona A; Erdem O; Dizdaroglu M
DNA Repair (Amst); 2019 Mar; 75():48-59. PubMed ID: 30743082
[TBL] [Abstract][Full Text] [Related]
35. Y-box-binding protein 1 as a non-canonical factor of base excision repair.
Alemasova EE; Moor NA; Naumenko KN; Kutuzov MM; Sukhanova MV; Pestryakov PE; Lavrik OI
Biochim Biophys Acta; 2016 Dec; 1864(12):1631-1640. PubMed ID: 27544639
[TBL] [Abstract][Full Text] [Related]
36. PARP1 Incises Abasic Sites and Covalently Cross-links to 3'-DNA Termini via Cysteine Addition Not Reductive Amination.
Wei X; Yang K
Biochemistry; 2023 May; 62(10):1527-1530. PubMed ID: 37094109
[TBL] [Abstract][Full Text] [Related]
37. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
[TBL] [Abstract][Full Text] [Related]
38. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
[TBL] [Abstract][Full Text] [Related]
39. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Hombach-Klonisch S; Kalantari F; Medapati MR; Natarajan S; Krishnan SN; Kumar-Kanojia A; Thanasupawat T; Begum F; Xu FY; Hatch GM; Los M; Klonisch T
Mol Oncol; 2019 Feb; 13(2):153-170. PubMed ID: 30289618
[TBL] [Abstract][Full Text] [Related]
40. Insight into DNA substrate specificity of PARP1-catalysed DNA poly(ADP-ribosyl)ation.
Matta E; Kiribayeva A; Khassenov B; Matkarimov BT; Ishchenko AA
Sci Rep; 2020 Feb; 10(1):3699. PubMed ID: 32111879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
